The SEC filings page for OnKure Therapeutics, Inc. (OKUR) provides access to the company’s official regulatory disclosures as a clinical-stage biopharmaceutical issuer listed on the Nasdaq Global Market. These documents offer detailed information about its precision oncology programs, financial condition, and capital markets activities, complementing the high-level descriptions found in press releases.
Through its periodic reports on Forms 10-K and 10-Q, OnKure describes its focus on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by current therapies. These filings expand on the company’s strategy around PI3Kα-targeted programs, including its lead candidate OKI-219 and its PI3Kα pan-mutant and other discovery-stage efforts, and include sections such as “Risk Factors” that outline scientific, clinical, regulatory, and financial risks.
Current reports on Form 8-K capture material events between periodic filings. For example, OnKure has filed 8-Ks to report quarterly financial results and to disclose entry into a sales agreement with Leerink Partners LLC for an at-the-market offering program of its Class A common stock. That agreement allows the company, subject to specified parameters and an effective shelf registration statement on Form S-3, to sell shares through Leerink Partners acting as sales agent, with compensation based on a percentage of gross proceeds.
On this page, users can review new and historical SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and registration statements such as Form S-3 referenced in the at-the-market program. Stock Titan’s tools apply AI-powered summaries to help explain the contents of lengthy filings, highlight key items like clinical development updates, capital raising arrangements, and risk disclosures, and make it easier to track how OnKure’s regulatory narrative evolves over time.
OnKure Therapeutics, Inc. Schedule 13G reports that RA Capital-related reporting persons collectively beneficially own 4,038,715 shares of Class A common stock, representing 9.99% of the class under a beneficial ownership blocker. The Fund directly holds 3,998,332 shares and pre-funded warrants exercisable for up to 128,174 shares.
The filing states the 9.99% figure is calculated using 13,673,565 shares outstanding as of March 11, 2026, plus 26,713,636 shares issued in a private placement that closed March 31, 2026, and 40,383 shares issuable upon exercise of the Pre-Funded Warrants.
OnKure Therapeutics, Inc. reported that President and CEO Nicholas A. Saccomano received a grant of employee stock options covering 330,000 shares of Class A Common Stock. The options have an exercise price of $4.07 per share and expire on March 31, 2036.
According to the filing, Saccomano holds 330,000 options following this grant, all as direct holdings. The award vests over time, with 1/48th of the option shares vesting on May 1, 2026 and monthly thereafter, contingent on his continued service with the company.
OnKure Therapeutics, Inc. reported that Chief Financial Officer Jason A. Leverone received an employee stock option grant covering 110,000 shares of Class A common stock. The options have an exercise price of $4.07 per share and expire on March 31, 2036.
According to the vesting schedule, 1/48th of the shares subject to the option will vest on May 1, 2026 and monthly thereafter, as long as he continues as a service provider through each vesting date. Following this grant, he holds 110,000 stock options directly.
Hartley Dylan reported acquisition or exercise transactions in this Form 4 filing.
OnKure Therapeutics, Inc. reported that Chief Scientific Officer Dylan Hartley received a grant of 110,000 employee stock options to buy Class A Common Stock at $4.07 per share. These options expire on March 31, 2036 and function as equity-based compensation rather than an open-market share purchase.
According to the vesting terms, 1/48th of the options will vest on May 1, 2026 and then monthly thereafter, as long as Hartley continues as a service provider. After this grant, Hartley directly holds 110,000 options covering an equal number of Class A Common shares.
OnKure Therapeutics, Inc. Chief Medical Officer Samuel Agresta reported a compensation-related grant of 110,000 employee stock options to buy Class A Common Stock. The options carry an exercise price of $4.07 per share and expire on March 31, 2036.
According to the filing, 1/48th of the options will vest on May 1, 2026 and then monthly thereafter, as long as he continues as a service provider. Following this grant, he holds 110,000 derivative securities directly, with no open-market buying or selling reported.
OnKure Therapeutics director Liam Ratcliffe received a new stock option grant as part of compensation. The award covers 15,300 options to buy Class A common stock at an exercise price of $4.14 per share, expiring on March 30, 2036.
These options vest over time: 1/36 of the grant vests on April 30, 2026 and 1/36 on the last day of each following month, as long as he continues as a service provider. After this grant, he holds 15,300 stock options directly from this award.
OnKure Therapeutics, Inc. director Liam Ratcliffe filed a Form 3 insider ownership report for the company. The data provided show no reported purchases, sales, option exercises, gifts, or other insider transactions, indicating this filing is purely an initial ownership disclosure without trading activity.
OnKure Therapeutics reports a Schedule 13G disclosing beneficial ownership stakes by Acorn-related entities and Anders Hove. The filing shows combined reported holdings of several Acorn entities and Mr. Hove ranging from 1,854,525 shares (4.5%) to 3,924,037 shares (9.5%) as of March 27, 2026. Percentages are calculated on a 41,471,564 share base that includes outstanding shares, a March 27, 2026 private placement, and warrants exercisable subject to a 9.9% blocker.
The cover-page comments note that reported share counts include shares issuable upon exercise of warrants and that certain exercises are limited by the 9.9% Blocker.
OnKure Therapeutics, Inc. entered into a private placement financing with institutional investors, agreeing to sell 26,713,636 Class A common shares at $4.15 per share and pre-funded warrants to purchase 9,430,959 shares at $4.1499 per underlying share, for expected gross proceeds of about $150.0 million before fees. The company plans to use the net proceeds to advance its next-generation PI3Kα pan-mutant programs in breast cancer and vascular anomalies and for working capital and general corporate purposes.
Investors receive registration rights for resale of the shares and warrant shares, and the lead investor obtains a board designee right, under which Dr. Liam Ratcliffe will join the board as a Class I director contingent on closing. Executives and directors agreed to a lock-up, and the company agreed to restrictions on new equity issuances and certain corporate actions for at least 180 days after closing and until the resale registration is effective. OnKure also provided pipeline updates, including plans to file INDs for OKI-345 and OKI-355 in the first half of 2027, progress in the PIKture-01 Phase 1a/1b trial of OKI-219, and a decision not to pursue further independent development of OKI-219 while it focuses on its PI3Kα pan-mutant inhibitors.
OnKure Therapeutics President and CEO Nicholas A. Saccomano reported a small tax-related sale of shares. He sold 86 shares of Class A Common Stock on March 23, 2026 at a weighted average price of $4.1565 per share.
According to the disclosure, these shares were automatically sold to cover tax withholding obligations tied to the vesting of restricted stock units under the company’s 2023 RSU Equity Incentive Plan. After this transaction, he directly holds 7,333 shares of Class A Common Stock.